Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa
Lilly vows to do another Phase II in effort to replicate an earlier study that showed efficacy for the novel schizophrenia drug over placebo.
Lilly vows to do another Phase II in effort to replicate an earlier study that showed efficacy for the novel schizophrenia drug over placebo.